$KDNY
Chinook Therapeutics Inc
PRICE
$15.01 ▲8.375%
Last Close
VOLUME
1,180,370
DAY RANGE
13.71 - 15.47
52 WEEK
10.48 - 19.85
Key Metrics
Market Cap
828.21 M
Beta
1.27
Avg. Volume
527.60 K
Shares Outstanding
55.18 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-11
Next Dividend Date
Company Information
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook's lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways.
CEO: Stephen Isaacs
Website: /www.chinooktx.com
HQ: 740 Heinz Ave Berkeley, 94710-2748 California
Related News